



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MS181

Cat. No.:	HY-158239
Molecular Formula:	C ₃₉ H ₄₁ N ₁₁ O ₆
Molecular Weight:	759.81
Target:	E1/E2/E3 Enzyme; PROTACs
Pathway:	Metabolic Enzyme/Protease; PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	MS181 (compound 1) is a potent cereblon (CRBN)-recruiting and EED-binding polycomb repressive complex 1 (PRC1) PROTAC degrader. MS181 decreases the expression of EED, EZH2, SUZ12, BMI1 and RING1B. MS181 shows antiproliferative activity (Structure Note: Red, EED binder (HY-158771); Blue, CRBN ligand (HY-41547); Black, Linker HY-131717) ^[1] .								
In Vitro	<p>MS181 (compound 1) (0, 0.1, 0.3, 1, 3, 10 μM; 24 h) decreases the expression of EED, EZH2, SUZ12, BMI1 and RING1B in a dose dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>K562 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 0.1, 0.3, 1, 3, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Decreased the expression of EED, EZH2, SUZ12, BMI1 and RING1B, H3K27me3 in a dose dependent manner, showed no changes in the histone H3 lysine 27 trimethylation (H3K27me3) mark catalyzed by the PRC2 complex.</td> </tr> </table>	Cell Line:	K562 cells	Concentration:	0, 0.1, 0.3, 1, 3, 10 μM	Incubation Time:	24 h	Result:	Decreased the expression of EED, EZH2, SUZ12, BMI1 and RING1B, H3K27me3 in a dose dependent manner, showed no changes in the histone H3 lysine 27 trimethylation (H3K27me3) mark catalyzed by the PRC2 complex.
Cell Line:	K562 cells								
Concentration:	0, 0.1, 0.3, 1, 3, 10 μM								
Incubation Time:	24 h								
Result:	Decreased the expression of EED, EZH2, SUZ12, BMI1 and RING1B, H3K27me3 in a dose dependent manner, showed no changes in the histone H3 lysine 27 trimethylation (H3K27me3) mark catalyzed by the PRC2 complex.								
In Vivo	<p>MS181 (50 mg/kg; i.p.; once) shows bioavailable in mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male swiss albino mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; once</td> </tr> <tr> <td>Result:</td> <td>Showed above 1 μM for the first 2 h and maintained above 0.50 μM for 8 h post in the plasma concentration.</td> </tr> </table>	Animal Model:	Male swiss albino mice ^[1]	Dosage:	50 mg/kg	Administration:	i.p.; once	Result:	Showed above 1 μM for the first 2 h and maintained above 0.50 μM for 8 h post in the plasma concentration.
Animal Model:	Male swiss albino mice ^[1]								
Dosage:	50 mg/kg								
Administration:	i.p.; once								
Result:	Showed above 1 μM for the first 2 h and maintained above 0.50 μM for 8 h post in the plasma concentration.								

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA